Innoviva (INVA): Affordable Growth Stock at a Reasonable Valuation
Innoviva Inc INVA
$20.97
▼ -1.18%
($-0.25)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$21.07
Prev Close
$21.22
Day Range
$20.82 – $21.08
52W Range
$16.52 – $25.15
Market Cap
$1.55B
P/E (TTM)
3.08
Beta
0.35
EPS (TTM)
$5.94
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-10-05 |
| Shares Out. | 73,810,000 |
| Website | inva.com/ ↗ |
| Phone | 13026587581 |
| Employees | 159 |
| Revenue | $98.0M |
| Gross Profit | $75.8M |
| Net Income | $186.6M |
| Free Cash Flow | $182.0M |
| Total Assets | $1.84B |
| Total Liabilities | $494.9M |
| Equity | $1.34B |
About Innoviva Inc
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Innoviva Inc is a publicly traded company under the ticker symbol INVA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)